First Forearm Transplantation: Outcome at 3 Years

Abstract

We here report on the surgical procedure, postoperative course and functional results at 3 years following the first bilateral forearm transplantation. A 41-year-old male underwent bilateral forearm transplantation on February 17, 2003. After ATG induction therapy, tacrolimus, prednisone and MMF were given for maintenance immunosuppression. At 16 months, MMF was switched to everolimus. Hand function, histology, immunohistochemistry, radiomorphology, motor and nerve conduction and somatosensory-evoked potentials were investigated at frequent intervals. A total of six rejection episodes required treatment with either steroids, basiliximab, ATG, alemtuzumab or tacrolimus dose augmentation. At 3 years, the patient is free of clinical signs of rejection despite a persisting minimal perivascular lymphocytic dermal infiltrate. No signs of myointimal proliferation in graft vessels were seen. Motor function continuously improved, resulting in satisfactory hand function. Intrinsic hand muscle function was first observed at 16 months and continues to improve. Although discrimination of hot and cold recovered, overall sensitivity remains poor. The patient is satisfied with the outcome. Bilateral forearm transplantation represents a novel therapeutic option after loss of forearms. † These authors contributed equally to this work.

Molecular Markers and Targeted Therapy of Skin Rejection in Composite Tissue Allotransplantation

“…Patients: Detailed descriptions of patients and the clinical courses were published previously (3)(4)(5)11,12). In brief, five patients (four male and one Efomycine M: Efomycine M was purified as described earlier (15,16 Figure 1F) and did not correlate with severity of rejection (cc = −0.071).…”

Targeting the Kv1.3 potassium channel for immunosuppression in vascularized composite allotransplantation - a pilot study

“…Functional and esthetic outcomes in over 75 hand/forearm and 20 facial transplants to date are good to excellent [1][2][3][4][5][6][7][8][9]. However, life-long immunosuppression required to ensure graft survival is associated with a wide range of side effects [7,[10][11][12] and introduction of immunosuppressive-sparing protocols is needed.…”

Clinical Immunosuppression in Solid Organ and Composite Tissue Allotransplantation

“…In 1954, Dr J. Murray was presented with the unique opportunity to transplant a human kidney between identical twins without facing the challenges of acute or chronic allograft rejection as well as side effects of long-term immunosuppression (1,2). Adding to scientific knowledge through basic research helped us to perform complex vascularized composite allotransplants (VCA) like the hand and face today and vascularized tissues recovered from a different individual will soon be extended to all reconstructive transplant procedures currently requiring autologous tissues (3)(4)(5). The development of novel surgical techniques and the discovery of potent immunosuppressive drugs in the second half of the 20 th century propelled the clinical development of organ transplantation (6).…”